PTN - Mergers and acquisitions

Only FDA-Approved As-Needed Treatment For The Approximately 6 Million Premenopausal Women Who Suffer From Hypoactive Sexual Desire Disorder (HSDD) Vyleesi® has experienced 8 Consecutive Quarters of Double-Digit Prescription Growth Acquisition Adds Another Commercial Stage, Patent Protected Product to Cosette's Rapidly Expanding Women's Health Portfolio Cosette Pharmaceuticals, Inc. ("Cosette"), a US-based specialty pharmaceutical company with a focus on women's health and cardiovascular medicines, has completed the acquisition of Vyleesi® from Palatin Technologies, Inc. (NYSE:PTN), which includes 5 Orange Book listed patents with protection up to 2041. Palatin and Cosette will ens